Reply to Martin and Dauby-Reference-Cited by-同舟云学术

Reply to Martin and Dauby

Published:2022-11-16 Issue:7 Volume:76 Page:1344-1345
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Kling Kerstin¹^ORCID,Domingo Cristina²,Bogdan Christian³,Wilder-Smith Annelies⁴⁵,Harder Thomas¹

Affiliation:

1. Department of Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute , Berlin , Germany

2. Center for International Health Protection, Robert Koch Institute , Berlin , Germany

3. Mikrobiologisches Institut – Klinische Mikrobiologie, Immunologie und Hygiene, Friedrich Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen , Erlangen , Germany

4. Heidelberg Institute of Global Health, University of Heidelberg , Heidelberg , Germany

5. Institute of Social and Preventive Medicine, University of Bern , Bern , Switzerland

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac891/47882100/ciac891.pdf

Reference9 articles.

1. Guiding yellow fever vaccination strategy worldwide: booster = better?;Martin;Clin Infect Dis,2023

2. 17DD Yellow fever revaccination and heightened long-term immunity in populations of disease-endemic areas, Brazil;Campi-Azevedo;Emerg Infect Dis,2019

3. Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination;Kongsgaard;Sci Rep,2017

4. Questions regarding the safety and duration of immunity following live yellow fever vaccination;Amanna;Expert Rev Vaccines,2016

5. Ontogeny of early life immunity;Dowling;Trends Immunol,2014